# Immetas Therapeutics

> Immetas Therapeutics is a New Jersey biotech building drugs that target the chronic, low-grade inflammation that drives aging and age-related disease - what scientists call 'inflammaging.' Founded in 2018 by drug-development veteran J. Gene Wang and Harvard aging researcher David Sinclair, the company designs bispecific antibodies and other biologics to reprogram the innate immune system, aiming to treat age-related cancers and inflammatory and autoimmune disease. It raised an $11M Series A from Morningside Ventures in 2020 and partners with GC Biopharma on mRNA therapeutics.

- **Founded:** 2018
- **Headquarters:** East Hanover, New Jersey, United States
- **Founders:** J. Gene Wang, MD, PhD (Co-Founder & CEO), David Sinclair, PhD (Co-Founder (Scientific) / Professor of Genetics, Harvard Medical School)
- **Team size:** Small (single-digit to low double-digit employees; ~3 listed on data providers)
- **Products:** Bispecific antibody lead program, Inflammasome modulation platform, mRNA therapeutics (with GC Biopharma)
- **Notable:** Closed an $11M Series A in 2020 with Morningside Ventures as sole investor, Co-founded by Harvard aging scientist David Sinclair, named to TIME's 50 Most Influential People in Healthcare (2018), Secured a research collaboration with GC Biopharma for mRNA therapeutics in autoimmune disease (2023)

## Products & services

- **Bispecific antibody lead program** — A series of bispecific antibodies designed to regulate inflammation in the tumor microenvironment and overcome resistance to conventional immune checkpoint therapies.
- **Inflammasome modulation platform** — A proprietary approach based on selective modulation of inflammasomes, key sensors and mediators of the innate immune pathway, used to build biologic and small-molecule programs in cancer and autoimmunity.
- **mRNA therapeutics (with GC Biopharma)** — Discovery and development of mRNA-based therapeutics for autoimmune diseases, combining Immetas' innate-immune payload molecules with GC Biopharma's mRNA and lipid nanoparticle (LNP) delivery platforms.

## Achievements

- Closed an $11M Series A in 2020 with Morningside Ventures as sole investor
- Co-founded by Harvard aging scientist David Sinclair, named to TIME's 50 Most Influential People in Healthcare (2018)
- Secured a research collaboration with GC Biopharma for mRNA therapeutics in autoimmune disease (2023)
- Built a discovery platform around inflammasome modulation spanning oncology and autoimmunity

## Latest updates

- **2023-10** — Announced a research collaboration with GC Biopharma to discover and develop mRNA therapeutics for autoimmune diseases.
- **2020-09** — Announced $11M Series A financing led solely by Morningside Ventures to advance inflammation-in-aging research and bispecific antibody programs.

## Links

- Website: https://immetas.com
- LinkedIn: https://www.linkedin.com/company/immetas-therapeutics

---

Profile page: https://yespress.io/immetas-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-14